Advertisement
Canada markets close in 1 hour 15 minutes

  • S&P/TSX

    22,427.18
    +127.35 (+0.57%)
     

  • S&P 500

    5,290.63
    -6.47 (-0.12%)
     

  • DOW

    39,902.63
    +33.25 (+0.08%)
     

  • CAD/USD

    0.7347
    +0.0001 (+0.02%)
     

  • CRUDE OIL

    80.08
    +0.85 (+1.07%)
     

  • Bitcoin CAD

    90,574.30
    +1,980.23 (+2.24%)
     

  • CMC Crypto 200

    1,358.82
    -15.03 (-1.09%)
     

  • GOLD FUTURES

    2,422.10
    +36.60 (+1.53%)
     

  • RUSSELL 2000

    2,092.12
    -4.13 (-0.20%)
     

  • 10-Yr Bond

    4.4180
    +0.0410 (+0.94%)
     

  • NASDAQ

    16,642.29
    -56.03 (-0.34%)
     

  • VOLATILITY

    12.22
    -0.20 (-1.61%)
     

  • FTSE

    8,420.26
    -18.39 (-0.22%)
     

  • NIKKEI 225

    38,787.38
    -132.88 (-0.34%)
     

  • CAD/EUR

    0.6753
    -0.0003 (-0.04%)
     
MARKETS LIVE BLOG:

STOCKS TREAD WATER WITH DOW EYEING 40,000 MARK AGAIN

GameStop shares sink further after games retailer said it expects Q1 sales to decline

Curis to Release First Quarter 2024 Financial Results and Hold Conference Call on May 7, 2024

PR Newswire
·2 min read

LEXINGTON, Mass., April 30, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will release its first quarter 2024 financial results on Tuesday, May 7, 2024, at 8:00 a.m. ET. Management will host a conference call on the same day at 8:30 a.m. ET.

(PRNewsfoto/Curis, Inc.)
(PRNewsfoto/Curis, Inc.)

To access the live conference call, please dial (800)-836-8184 from the United States or (646)-357-8785 from other locations, shortly before 8:30 a.m. ET. The conference call can also be accessed on the Curis website at www.curis.com in the 'Investors' section. A replay of the conference call will be available on the Curis website shortly after completion of the call.

About Curis, Inc.

Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor. Emavusertib is currently undergoing testing in the Phase 1/2 TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase 1/2 TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS), both of which have received Orphan Drug Designation from the U.S. Food and Drug Administration. Emavusertib is also being evaluated as a frontline combination therapy with azacitidine and venetoclax in patents with AML. Curis, through its 2015 collaboration with Aurigene, has the exclusive license to emavusertib (CA-4948). Curis licensed its rights to Erivedge® to Genentech, a member of the Roche Group, under which they are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at www.curis.com

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-to-release-first-quarter-2024-financial-results-and-hold-conference-call-on-may-7-2024-302131015.html

SOURCE Curis, Inc.